442 related articles for article (PubMed ID: 21908036)
1. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Fayad ZA; Mani V; Woodward M; Kallend D; Abt M; Burgess T; Fuster V; Ballantyne CM; Stein EA; Tardif JC; Rudd JH; Farkouh ME; Tawakol A;
Lancet; 2011 Oct; 378(9802):1547-59. PubMed ID: 21908036
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
Fayad ZA; Mani V; Woodward M; Kallend D; Bansilal S; Pozza J; Burgess T; Fuster V; Rudd JH; Tawakol A; Farkouh ME
Am Heart J; 2011 Aug; 162(2):214-221.e2. PubMed ID: 21835280
[TBL] [Abstract][Full Text] [Related]
3. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
Lüscher TF; Taddei S; Kaski JC; Jukema JW; Kallend D; Münzel T; Kastelein JJ; Deanfield JE;
Eur Heart J; 2012 Apr; 33(7):857-65. PubMed ID: 22345126
[TBL] [Abstract][Full Text] [Related]
4. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study.
Duivenvoorden R; Mani V; Woodward M; Kallend D; Suchankova G; Fuster V; Rudd JHF; Tawakol A; Farkouh ME; Fayad ZA
JACC Cardiovasc Imaging; 2013 Oct; 6(10):1087-1094. PubMed ID: 24135322
[TBL] [Abstract][Full Text] [Related]
5. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
6. Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study.
Mani V; Woodward M; Samber D; Bucerius J; Tawakol A; Kallend D; Rudd JH; Abt M; Fayad ZA
Int J Cardiovasc Imaging; 2014 Mar; 30(3):571-82. PubMed ID: 24458953
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
[TBL] [Abstract][Full Text] [Related]
8. Does Vascular Calcification Accelerate Inflammation?: A Substudy of the dal-PLAQUE Trial.
Joshi FR; Rajani NK; Abt M; Woodward M; Bucerius J; Mani V; Tawakol A; Kallend D; Fayad ZA; Rudd JH
J Am Coll Cardiol; 2016 Jan; 67(1):69-78. PubMed ID: 26764069
[TBL] [Abstract][Full Text] [Related]
9. Dalcetrapib: turning the tide for CETP inhibition?
Stroes ES; van Wijk DF
Lancet; 2011 Oct; 378(9802):1529-30. PubMed ID: 21908039
[No Abstract] [Full Text] [Related]
10. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
Stein EA; Roth EM; Rhyne JM; Burgess T; Kallend D; Robinson JG
Eur Heart J; 2010 Feb; 31(4):480-8. PubMed ID: 20097702
[TBL] [Abstract][Full Text] [Related]
12. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC
Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
[TBL] [Abstract][Full Text] [Related]
13. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
Ballantyne CM; Miller M; Niesor EJ; Burgess T; Kallend D; Stein EA
Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
[TBL] [Abstract][Full Text] [Related]
14. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
15. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.
Lo J; Lu MT; Ihenachor EJ; Wei J; Looby SE; Fitch KV; Oh J; Zimmerman CO; Hwang J; Abbara S; Plutzky J; Robbins G; Tawakol A; Hoffmann U; Grinspoon SK
Lancet HIV; 2015 Feb; 2(2):e52-63. PubMed ID: 26424461
[TBL] [Abstract][Full Text] [Related]
16. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.
Ray KK; Ditmarsch M; Kallend D; Niesor EJ; Suchankova G; Upmanyu R; Anzures-Cabrera J; Lehnert V; Pauly-Evers M; Holme I; Štásek J; van Hessen MW; Jones P;
Eur Heart J; 2014 Jul; 35(27):1792-800. PubMed ID: 24639426
[TBL] [Abstract][Full Text] [Related]
17. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.
Tardif JC; Dubé MP; Pfeffer MA; Waters DD; Koenig W; Maggioni AP; McMurray JJV; Mooser V; White HD; Heinonen T; Black DM; Guertin MC;
Am Heart J; 2020 Apr; 222():157-165. PubMed ID: 32087417
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation.
Kastelein JJ; Duivenvoorden R; Deanfield J; de Groot E; Jukema JW; Kaski JC; Münzel T; Taddei S; Lehnert V; Burgess T; Kallend D; Lüscher TF
Curr Med Res Opin; 2011 Jan; 27(1):141-50. PubMed ID: 21128879
[TBL] [Abstract][Full Text] [Related]
19. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.
Tardif JC; Rhainds D; Brodeur M; Feroz Zada Y; Fouodjio R; Provost S; Boulé M; Alem S; Grégoire JC; L'Allier PL; Ibrahim R; Guertin MC; Mongrain I; Olsson AG; Schwartz GG; Rhéaume E; Dubé MP
Circ Cardiovasc Genet; 2016 Aug; 9(4):340-8. PubMed ID: 27418594
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
Derks M; Abt M; Mwangi A; Meneses-Lorente G
Eur J Clin Pharmacol; 2010 Aug; 66(8):775-83. PubMed ID: 20521033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
